📇 Rhumatologue · PESSAC CEDEX · (33) · Hospitalier

M FLORIAN POULLENOT

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
36 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
144.4 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PESSAC CEDEX (33)HospitalierRPPS 10100543494

Publications actives

17 publications sur 5 ans

📊 Reconnaissance scientifique : 21/100📝 107 articles publiés🇫🇷 Publications académiques françaises (8)

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease

Inflammatory bowel diseases · 2017

📚 201 citations🎯 RCR 9.79Top 3% NIH🔓 Open Access📄 PDF gratuit ↗

Clinical classification of adult patients with chronic intestinal failure due to benign disease: An international multicenter cross-sectional survey

Clinical nutrition (Edinburgh, Scotland) · 2018

📚 115 citations🎯 RCR 7.90Top 4% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study

Journal of Crohn's & colitis · 2021

📚 62 citations🎯 RCR 5.17Top 7% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background The approved maintenance regimens for ustekinumab in Crohn’s disease [CD] are 90 mg every 8 or 12 weeks. Some patients will respond partially to ustekinumab or will experience a secondary loss of response. It remains poorly known if these patients may benefit from shortening the interval between injections. Methods All patients with active CD, as defined by Harvey–Bradshaw score ≥ 4 and one objective sign of inflammation [C-reactive protein &gt; 5 mg/L and/or faecal calprotectin &gt; 250 µg/g and/or radiological and/or endoscopic evidence of disease activity] who required ustekinumab dose escalation to 90 mg every 4 weeks for loss of response or incomplete response to ustekinumab 90 mg every 8 weeks were included in this retrospective multicentre cohort study. Results One hundred patients, with a median age of 35 years [interquartile range, 28–49] and median disease duration of 12 [7–20] years were included. Dose intensification was performed after a median of 5.0 [2.8–9.0] months of ustekinumab treatment and was associated with corticosteroids and immunosuppressants in respectively 29% and 27% of cases. Short-term clinical response and clinical remission were observed in respectively 61% and 31% after a median of 2.4 [1.3–3.0] months. After a median follow-up of 8.2 [5.6–12.4] months, 61% of patients were still treated with ustekinumab, and 26% were in steroid-free clinical remission. Among the 39 patients with colonoscopy during follow-up, 14 achieved endoscopic remission [no ulcers]. At the end of follow-up, 27% of patients were hospitalized, and 19% underwent intestinal resection surgery. Adverse events were reported in 12% of patients, including five serious adverse events. Conclusion In this multicentre study, two-thirds of patients recaptured response following treatment intensification with ustekinumab 90 mg every 4 weeks.

Cookies & analyse de trafic

M FLORIAN POULLENOT

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (36) — classées par pathologie

Transversal17

Anti-TNF6

Épidémiologie & registres3

Vraie vie / RWE3

Anti-IL-232

Pharmacovigilance2

Économie santé1

Pédiatrie1

Qualité de vie / PROMs1

Recommandations1

Revue / méta-analyse1

Revue générale1

Datasets & protocoles partagés

Partager cette fiche